Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02936635 · ClinicalTrials.gov registry record · Phase 3
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3 study, sponsored by Cytokinetics.
- Completed
- Registry status
- Phase 3
- Development phase
- 280
- Enrollment target
NCT02936635: Completed Phase 3 study, sponsored by Cytokinetics.
NCT02936635 is a Phase 3 study that has completed, run by Cytokinetics. The registered enrollment target is 280 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (64% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02936635, a Phase 3 study, has completed, sponsored by Cytokinetics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 280 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the long-term safety and tolerability of tirasemtiv in patients with ALS who had completed the double-blind placebo-controlled study of tirasemtiv in ALS (CY 4031).
Primary Outcome
The number of participants with adverse events was used as the measure for the long-term safety and tolerability of tirasemtiv.
Interventions
- DRUG tirasemtiv
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2016-10-17 |
| Est. Completion | 2018-10-26 |
| Phase | Phase 3 |
What the finished NCT02936635 record still lists
NCT02936635 is an interventional study that assigns participants to a tested intervention. The registered 280 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (64% lower).
The record links to 0 conditions, and to 1 intervention - of which tirasemtiv is the first listed.
NCT02936635 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02936635 about?
NCT02936635 is a clinical study titled "A Study for Patients Who Completed VITALITY-ALS (CY 4031)". The purpose of this study is to assess the long-term safety and tolerability of tirasemtiv in patients with ALS who had completed the double-blind placebo-controlled study of tirasemtiv in ALS (CY 4031).
What is the current status of trial NCT02936635?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 280 participants. The study started on 2016-10-17. Estimated completion is 2018-10-26.
What interventions are being tested in trial NCT02936635?
The interventions under investigation include: tirasemtiv (DRUG).
Who is sponsoring clinical trial NCT02936635?
This trial is sponsored by Cytokinetics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02936635's enrollment target sits among peer trials
280 1195th of 2000 higher than 802 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04084730 · 280 participants · Phase 2
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
- NCT04518657 · 280 participants · NA
Internet-Delivered Lifestyle Physical Activity Intervention for Cognitive Processing Speed in Multiple Sclerosis
- NCT04634916 · 280 participants · NA
Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
- NCT04829617 · 280 participants · NA
Promoting Well-being and Health in Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI